Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
Completed
Massachusetts General Hospital
Phase 4
2005-06-01
The purpose of this study is to obtain data investigating the safety and efficacy of
eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep
disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine
correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more
effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in
sleep will be associated with improvement in overall PTSD symptoms, and patients with
PTSD-related sleep disturbances will have abnormal levels of stress hormones.
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
Completed
Sunovion
Phase 4
2005-06-01
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of
insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will
receive an approved anxiolytic agent and will be randomized to nightly therapy with either
eszopiclone or placebo.
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
Completed
Sanofi
Phase 4
2006-01-01
Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem
Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young
Volunteers, Using Flurazepam 30 mg as an External Comparator
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
Completed
Sunovion
Phase 3
2003-10-01
To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects
with primary insomnia on subjective sleep measures, compared to placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
